Transformative Urologic Care in a Pioneering Health System
The Fox Chase–Temple Urologic Institute represents an innovative partnership that unites the expertise of distinguished institutions within one health system in the pursuit of groundbreaking oncologic and benign urology care.
Our multidisciplinary teams, composed of internationally recognized urologic leaders, address the most challenging genitourinary malignancies as well as complex benign urologic conditions. By employing state-of-the-art robotic, minimally invasive, and open surgical techniques, our specialists provide comprehensive oncologic, reconstructive, and prosthetic care.
Moreover, our cutting-edge translational research programs offer patients access to some of the world's most promising clinical trials. This unique fusion of advanced clinical discovery, innovative treatment delivery, and transformative care ensures that our patients receive the highest caliber of urologic care available today.
View this symposium presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education. Learn the most current strategies for optimally managing localized and advanced prostate cancer from the Fox Chase ...
Temple robotic surgeons are making it possible for more patients to receive lifesaving therapies after being told they were out of options.
Built on strength: world-class specialists, innovative researchers, and clinical leaders.
Where groundbreaking oncologic and benign care unite within one health system
Dr. Joshua Cohn, Fox Chase-Temple Urologic Institute Provider, discusses urinary incontinence in women, focusing on the etiology, prevalence and diagnostic evaluation. He also discusses the various treatment options that may be most helpful for each patient.
Could NanoKnife be the future of prostate cancer care?
Join Steve Sterious, MD FACS , Fox Chase-Temple Urologic Institute Provider, to discuss Aquablation and the changing surgical landscape of BPH.
Bladder removal is life-altering. This study examines when and why some patients may not need it.
Centralizing scientific discovery, advanced research, and clinical care—all for a new therapeutic pathway.
A Life-Saving Idea for Bladder Cancer Patients.
The artificial urinary sphincter is an implantable device designed to treat incontinence in prostate cancer survivors. The device has existed for 50 years, and in that time, best practices around its use have undergone several paradigm shifts.
Fox Chase Cancer Center’s urologic oncology group shares an educational video that provides instruction on how to perform a device-free, free-handed transperineal prostate biopsy.
Adaptive radiation therapy allows clinicians to make daily adjustments in a patient’s treatment in real time while the patient is on the treatment table based on the cancer’s response to the radiation, position of the tumor, and the location ...
Fighting for life everywhere she goes.
Digging into the "why" of racial disparity in kidney cancer outcomes.
Amoroso is part of the nurse-led dedicated intravesical clinic that helps optimize treatment for patients and workflow for other physicians and nurses.
Researchers at Fox Chase Cancer Center have developed a model that predicts disease recurrence and survival in patients with intermediate- and high-risk localized kidney cancer more accurately than existing prognostic models.
Fox Chase’s Alexander Kutikov, MD, FACS, is leading an international effort to create a centralized, streamlined, point-of-care resource for the management of adrenal masses.